Therapeutic evaluation of intralesional tranexamic acid in higher concentration for treatment of facial melasma
Keywords:
Melasma, Intralesional, tranexamic acid, melasma, intralesional, tranexamic acid, mMASIAbstract
Background Melasma is a chronic relapsing hyperpigmentary disorder. As the entire etiopathogenesis of melasma is not well understood, there are chances of development of new therapeutic modalities. Tranexamic acid (TXA) has been used in a variety of formulations; nevertheless, there are few research, data and opinions regarding the optimal dosage of intralesional TXA in melasma. Methods Total 32 patients were enrolled in our study from January 2023 to June 2023. Injection TXA (0.05 ml) was given intralesionally 1cm apart on entire facial melasma lesion and repeated after every 4 weeks till lesions cleared or a maximum of 6 sessions. Follow up was done at every visit and after 3 months of last session for relapse. Clinical improvement was measured by percentage reduction in mMASI at baseline, at every session and at follow up. Results More than 50% patients showed good to very good response with significant reduction in mMASI from 8th week onwards as compared to baseline. Most of the patients were satisfied with their recovery following therapy and reported no significant adverse effects. Conclusion TXA was found to be efficacious in all types of melasma. Better response was seen in epidermal and mixed types in comparison to dermal melasma. We recommend a dosage of 50mg/ml at monthly intervals as optimal dosage for an effective therapy in all types of melasma.References
Bandyopadhyay D. Topical treatment of melasma. Indian J Dermatol. 2009;54:303-9.
Werlinger KD, Guevara IL, González CM, Rincón ET, Caetano R, Haley RW, et al. Prevalence of self-diagnosed melasma among premenopausal Latino women in Dallas and Fort Worth, Tex. Arch Dermatol. 2007;143(3):424-5.
Rendon MI. Hyperpigmentation Disorders in Hispanic Population in the United States. J Drugs Dermatol. 2019;18(3):112-4.
Passeron T, Picardo M. Melasma, a photoaging disorder. Pigment Cell Melanoma Res. 2018;31(4):461–5.
Serre C, Busuttil V, Botto JM. Intrinsic and extrinsic regulation of human skin melanogenesis and pigmentation. Int J Cosmet Sci. 2018;40(4):328–47.
Kaur A, Bhalla M, Sarkar R. Tranexamic acid in melasma: a review. Pigment Int. 2020;7:12-25.
Zhu HJ, Yang XH. The clinical study of acidum tranexamicum on melasma. Pharm Prog. 2001;3:178-81.
Maeda K, Naganuma M. Topical trans-4 aminomethyl cyclohexane carboxylic acid prevents ultraviolet radiation-induced pigmentation. J Photochem Photobiol. 1998;47(2-3):136-41.
Del Rosario E, Florez-Pollack S, Zapata L Jr, Hernandez K, Tovar-Garza A, Rodrigues M, et al. Randomized, placebo-controlled, double-blind study of oral tranexamic acid in the treatment of moderate-to-severe melasma. J Am Acad Dermatol. 2018;78(2):363–9.
Krivokuca I, Lammers JW. Recurrent pulmonary embolism associated with a hemostatic drug: tranexamic acid. Clin Appl Thromb Hemost. 2011;17(1):106–7.
Pistor M. What is mesotherapy? Chir Dent Fr. 1976;46:59-60.
Abdalla MA. Melasma Clinical Features, Diagnosis, Epidemiology and Etiology: An Update Review. Siriraj Med J. 2021;73(12): 841–50.
Khurana VK, Misri RR, Agarwal S, Thole AV, Kumar S, Anand T. A randamised open level comparative study of oral and intralesonal microinjections of in patients of melasma. Indian J Dermatol Venereol Leprol. 2019;85:39-43.
Wongwicharm P, Sirithanabadeekul P. The effectiveness of localized intradermal microinjection of 50 mg/ml of tranexamic acid for melasma treatment in Thai patients: a pilot study. Thai J Pharm Sci. 2018;42:93-7.
Lee JH, Park JG, Lim SH, Kim JY, Ahn KY, Kim MY, et al. Localized intradermal microinjection of tranexamic acid for treatment of melasma in Asian patients: A preliminary clinical trial. Dermatologic Surg. 2006;32(5):626–31.
Lueangarun S, Sirithanabadeekul P, Wongwicharn P, Namboonlue C, Pacharapakornpong S, Juntongjin P, et al. Intradermal tranexamic acid injection for the treatment of melasma: a pilot study with 48-week follow-up. J Clin Aesthet Dermatol. 2020;13(8):36.
Verma YR, Mehta KS, Chauhan PS, Mahajan VK, Chandel M, Sharma HK, et al. Study of the therapeutic efficacy and safety of Intralesional Tranexamic Acid (25 mg/ml) for the treatment of melasma in male patients: A single centered “beforeafter” observational study. Int J Res Dermatol. 2021;7:827-34.
Pazyar N, Dezfuly MB, Hadibarhaghtalab M, Parvar SY, Molavi SN, Mapar MA, et al. Intradermal Injection of 100mg Tranexamic Acid Versus Topical 4% Hydroquinone for the Treatment of Melasma: A Randomized, Controlled Trial. J Clin Aesthet Dermatol. 2023;16(1):35.
Samanthula H, Koganti M, Chowdary N, Kurapati AS. A study of intradermal tranexamic acid for treatment in melasma patients. Int J Res Dermatol. 2020;6:632-6.
Pazyar N, Yaghoobi R, Zeynalie M, Vala S. Comparison of the e cacy of intradermal injected tranexamic acid vs hydroquinone cream in the treatment of melasma. Clin Cosmet Invest Dermatol. 2019;12:115-22.
Pazyar N, Molavi SN, Hosseinpour P, et al. Efficacy of intradermal injection of tranexamic acid and ascorbic acid versus tranexamic acid and placebo in the treatment of melasma: A split‐face comparative trial. Health Sci Rep. 2022;5(2):e537.
Adelia AL, Nurainiwati SA, Putra PY, Hapsari AS. Efficacy, effectiveness, and safety of combination laser and tranexamic acid treatment for melasma: A meta-analysis. Chinese J Plast Reconstruct Surg. 2023;5:153-8.
